Funding for this research was provided by:
Kite Pharma
Paracelsus Medical University
Article History
Received: 24 November 2022
Accepted: 29 November 2022
First Online: 31 January 2023
Conflict of interest
: G. Hopfinger: speakers’ bureau participation: Kite Pharma, Takeda, Roche, Celgene, GlaxoSmithKline, Gilead, Janssen, Novartis, Bristol Myers Squibb, BeiGene; honoraria: Kite Pharma, Takeda, Roche, Celgene, GlaxoSmithKline, Gilead, Janssen, Novartis, Bristol Myers Squibb, BeiGene; travel support: Roche, Jannssen. B. Rupp: honoraria from: Gilead; consultancy or advisory role for: Gilead. R. Greil: honoraria from Gilead, Celgene, Roche, Merck, Takeda, AstraZeneca, Novartis, Amgen, BMS, MSD, Sandoz, Abbvie, Gilead, Daiichi Sankyo, Sanofi; consultancy or advisory role for Gilead, Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Daiichi Sankyo, Sanofi; research funding: Celgene, Roche, Merck, Takeda, AstraZeneca, Novartis, Amgen, BMS, MSD, Sandoz, Abbvie, Gilead, Daiichi Sankyo; travel, accommodations, expenses: Roche, Amgen, Janssen, AstraZeneca, Novartis, MSD, Celgene, Gilead, BMS, Abbvie, Daiichi Sankyo.